cd5 car-t cells
Cell therapyexperimental
Clinical trial activity
12 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04594135)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Prolymphocytic, T-Cell · Phase 1/Phase 2
- Leukemia, T-Cell · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Early Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- T-cell surface glycoprotein CD5Immunity, passive
CD5 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07234110 | N/A | Sep 3, 2025 | Beijing Boren Hospital, China Academy of Chinese Medical Sciences |
| NCT07070323 | Phase 1/Phase 2 (Phase 2) | Jul 9, 2025 | Central People's Hospital of Zhanjiang, Government of China, Hacettepe University, People's Liberation Army of China, Shanghai Liquan Hospital |
| NCT07022964 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2025 | Government of China, Jiao Tong University, Shanghai Liquan Hospital |
| NCT06909474 | Phase 1 | Mar 27, 2025 | Chongqing Precision Biotech Co., Ltd |
| NCT06874946 | Phase 1/Phase 2 (Phase 2) | Feb 14, 2025 | Hebei Senlang Biotechnology Inc., Ltd., Peking University |
| NCT06633341 | Early Phase 1 (Phase 1) | Oct 20, 2024 | Yake Biotechnology Ltd., Zhejiang University |
| NCT06633354 | Early Phase 1 (Phase 1) | Oct 20, 2024 | Yake Biotechnology Ltd., Zhejiang University |
| NCT06420076 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2024 | Essen Biotech |
| NCT06316856 | Phase 1/Phase 2 (Phase 2) | Jun 18, 2024 | Government of China |
| NCT05596266 | Phase 1 | Oct 25, 2022 | Baoding Children's Hospital, Capital Medical University |
| NCT05032599 | Phase 1 | Sep 14, 2021 | Beijing Boren Hospital |
| NCT04594135 | Phase 1 | Nov 30, 2020 | iCell Gene Therapeutics, Peking University |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 1 | 2024 |
| Beijing Boren Hospital | Academic/Hospital | 2 | 1 | 2 | 2021 |
| Peking University | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Shanghai Liquan Hospital | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Yake Biotechnology Ltd. | Government | 2 | 0 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Baoding Children's Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Central People's Hospital of Zhanjiang | Academic/Hospital | 1 | 0 | 1 | 2025 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Chongqing Precision Biotech Co., Ltd | For profit | 1 | 1 | 1 | 2025 |
| Essen Biotech | For profit | 1 | 1 | 1 | 2024 |
| Hacettepe University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Hebei Senlang Biotechnology Inc., Ltd. | For profit | 1 | 0 | 1 | 2025 |
| iCell Gene Therapeutics | For profit | 1 | 1 | 1 | 2020 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2025 |
17 organizations
Page 1 / 1